This morning’s update highlights an in-line performance of key revenue drivers, but an expected £5m negative top line impact from currency. In addition, Vectura has taken the decision to partner its proprietary VR475 (EU) and VR647 (US) programmes, in line with our expectations. FY2018 R&D guidance has been lowered, with our £65m forecast remaining within the range. Finally, Mundipharma has terminated development of the VR2076 pMDI triple therapy, which we did not includ
04 Jan 2018
Trading and strategy update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Trading and strategy update
- Published:
04 Jan 2018 -
Author:
Dr Jens Lindqvist -
Pages:
4
This morning’s update highlights an in-line performance of key revenue drivers, but an expected £5m negative top line impact from currency. In addition, Vectura has taken the decision to partner its proprietary VR475 (EU) and VR647 (US) programmes, in line with our expectations. FY2018 R&D guidance has been lowered, with our £65m forecast remaining within the range. Finally, Mundipharma has terminated development of the VR2076 pMDI triple therapy, which we did not includ